Condition
SBRT clinical trials and research
As of November 12, 2026, Find a Trial lists 5 SBRT clinical trials that are recruiting, at sites in 4 countries (most in China (2), France (1), Belgium (1)). By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest SBRT clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer | — | Zaragoza, Zaragoza | Recruiting | Aug 21, 2026 |
| Single‑session high‑dose lung radiotherapy and its effects on outcomes and quality of life | — | Montpellier, ICM and 1 other locations | Recruiting | Mar 2, 2026 |
| Focused radiation plus nimotuzumab followed by tislelizumab for oligoprogressive recurrent or metastatic nasopharyngeal cancer after prior immunotherapy | Phase 2 | Xiamen, Fujian and 1 other locations | Recruiting | Nov 6, 2024 |
| Combining targeted radiation with immunotherapy for advanced oral and throat cancer | Phase 2 | Guangzhou, Guangdong | Recruiting | Jan 23, 2024 |
| Observational study on extreme hypofractionation for localized prostate cancer | — | Leuven, Vlaams Brabant | Recruiting | Apr 25, 2022 |
All recruiting trials (5)
-
Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer
This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.
-
Single‑session high‑dose lung radiotherapy and its effects on outcomes and quality of life
This study tests whether a single high‑dose session of SBRT (30–34 Gy) works and how it affects quality of life for adults with small primary non‑small cell lung cancers or up to three lung metastases who are inoperable or refuse surgery.
-
Focused radiation plus nimotuzumab followed by tislelizumab for oligoprogressive recurrent or metastatic nasopharyngeal cancer after prior immunotherapy
This trial will try focused stereotactic radiation together with the antibody nimotuzumab, followed by the PD‑1 drug tislelizumab, in people whose recurrent or metastatic nasopharyngeal cancer has progressed at 1–5 spots after prior anti–PD‑1 treatment.
-
Combining targeted radiation with immunotherapy for advanced oral and throat cancer
This study is testing a new treatment that combines targeted radiation with immunotherapy to see if it helps people with advanced oral and throat cancer before surgery.
-
Observational study on extreme hypofractionation for localized prostate cancer
This study tests a new type of radiation treatment for men with localized prostate cancer to see if giving higher doses in fewer sessions can work better and be safer than the usual methods.
Related topics
Quick answers
How many SBRT clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (2 trials), France (1 trial), Belgium (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.